APA (7th ed.) Citation

Kciuk, M., Wanke, K., Kruczkowska, W., Marciniak, B., & Kontek, R. (2025). Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. MDPI AG.

Chicago Style (17th ed.) Citation

Kciuk, Mateusz, Katarzyna Wanke, Weronika Kruczkowska, Beata Marciniak, and Renata Kontek. Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. MDPI AG, 2025.

MLA (9th ed.) Citation

Kciuk, Mateusz, et al. Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. MDPI AG, 2025.